MedTrace Logo

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05979857 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-11-22

No results posted yet for this study

Summary

The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.

Conditions

  • Lymphoma, Non-Hodgkin's, Adult

Interventions

DRUG

SP-3164

SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'

Sponsors & Collaborators

  • Salarius Pharmaceuticals, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-08-15
Completion
2027-08-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05979857 on ClinicalTrials.gov